| You
are here: Home: BCU 2|2003: Peter
Ravdin, MD, PhD: Select publications
Select publications
Treatment-related bone loss in breast cancer
Bryce CJ et al. Does short-term, intravenous, low dose
clodronate, administered with adjuvant chemotherapy for premenopausal
breast cancer reduce bone loss in the first year in patients?
Proc ASCO 2002; Abstract
270.
Delmas PD et al. Bisphosphonate risedronate prevents bone
loss in women with artificial menopause due to chemotherapy of breast
cancer: A double-blind, placebo-controlled study. J Clin
Oncol 1997;15(3):955-62. Abstract
Gasser JA et al. Intravenous administration of zoledronic
acid offers long-term protection against bone loss in rats induced
as a consequence of estrogen deprivation. Breast Cancer
Res Treat 2002; Abstract
274.
Gnant M et al. Changes in bone mineral density caused by
anastrozole or tamoxifen in combination with goserelin (±
zoledronate) as adjuvant treatment for hormone receptor-positive
premenopausal breast cancer: results of a randomized multicenter
trial. Breast Cancer Res Treat 2002; Abstract
12.
Holland D, Mortimer J. Impact of adjuvant chemotherapy
and amenorrhea on bone loss in premenopausal women with breast cancer.
Proc ASCO 1999; Abstract
Jakesz R et al. Randomized adjuvant trial of tamoxifen
and goserelin versus cyclophosphamide, methotrexate, and fluorouracil:
evidence for the superiority of treatment with endocrine blockade
in premenopausal patients with hormone-responsive breast cancer--Austrian
Breast and Colorectal Cancer Study Group Trial 5. J Clin
Oncol 2002;20(24):4621-7. Abstract
Pickering LM, Mansi JL. The role of bisphosphonates in
breast cancer management: Review article. Curr Med Res
Opin 2002;18(5):284-95. Abstract
Powles TJ et al. Oral clodronate and reduction in loss
of bone mineral density in women with operable primary breast cancer.
J Natl Cancer Inst. 1998;90(9):704-8. Abstract
Saarto T et al. Chemical castration induced by adjuvant
cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes
rapid bone loss that is reduced by clodronate: A randomized study
in premenopausal breast cancer patients. J Clin Oncol 1997;15(4):1341-7.
Abstract
Saarto T et al. Clodronate improves bone mineral density
in post-menopausal breast cancer patients treated with adjuvant
antioestrogens. Br J Cancer. 1997;75(4):602-5. Abstract
Saarto T et al. The effect of clodronate and antioestrogens
on bone loss associated with oestrogen withdrawal in postmenopausal
women with breast cancer. Br J Cancer 2001;84(8):1047-51.
Abstract
Sverrisdóttir A et al. Bone mineral density in
premenopausal patients in a randomized trial of adjuvant endocrine
therapy (ZIPP-TRIAL). Proc ASCO 2001; Abstract
96.
Vehmanen L et al. Long-term impact of chemotherapy-induced
ovarian failure on bone mineral density (BMD) in premenopausal breast
cancer patients. The effect of adjuvant clodronate treatment. Eur
J Cancer. 2001;37(18):2373-8. Abstract
Capecitabine in patients with metastatic breast cancer
Blum J. The role of capecitabine, an oral, enzymatically
activated fluoropyrimidine, in the treatment of metastatic breast
cancer. Oncologist 2001;6(1):56-64. Abstract
Crown J. Nonanthracycline containing docetaxel-based combinations
in metastatic breast cancer. Oncologist 2001;6 Suppl 3:17-21.
Abstract.
Gradishar WJ. Clinical status of capecitabine in the treatment
of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71.
Abstract
Jakob A et al. Capecitabine in patients with breast cancer
relapsing after high-dose chemotherapy plus autologous peripheral
stem cell transplantation--a phase II study. Anticancer
Drugs 2002;13(4):405-10. Abstract
Leonard RC et al. Capecitabine named-patient programme
for patients with advanced breast cancer. the UK experience.
Eur J Cancer 2002;38(15):2020-4. Abstract
Leonard RC. Oral fluoropyrimidines among the new drugs
for patients with metastatic breast cancer. Br J Cancer
2001;84(11):1437-42. Abstract
Maher JF, Villalona-Calero MA. Taxanes and capecitabine
in combination: Rationale and clinical results. Clin Breast
Cancer 2002;2(4):287-93. Abstract
O'Shaughnessy J et al. Superior survival with capecitabine
plus docetaxel combination therapy in anthracycline-pretreated patients
with advanced breast cancer: Phase III trial results. J
Clin Oncol 2002;20(12):2812-23. Abstract
Oshaughnessy JA et al. Randomized, open-label, phase II
trial of oral capecitabine (Xeloda) vs a reference arm of intravenous
CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line
therapy for advanced/metastatic breast cancer. Ann Oncol
2001;12(9):1247-54. Abstract
O'Shaughnessy J. Clinical experience of capecitabine in
metastatic breast cancer. Eur J Cancer 2002 Feb;38 Suppl
2:10-4. Abstract
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced
breast cancer pretreated with anthracyclines. Br J Cancer
2002;86(9):1367-72. Abstract
|
